CLINICAL TRIAL

Community Health Navigator Program for Chronic Kidney Diseases

Stage III
Recruiting · 18+ · All Sexes · Calgary, Canada

This study is evaluating whether a patient navigation program can improve care for patients with long-term health conditions.

See full description

About the trial for Chronic Kidney Diseases

Eligible Conditions
Heart Failure · Heart Diseases · Chronic Kidney Disease (CKD) · Coronary Artery Disease · Chronic Obstructive Pulmonary Disease (COPD) · Asthma · Myocardial Ischemia · Hypertension · Ischemic Heart Disease · Diabetes Mellitus, Type 2 · Congestive Heart Failure (CHF) · Pulmonary Disease, Chronic Obstructive · Kidney Diseases · Renal Insufficiency, Chronic · Lung Diseases, Obstructive

Treatment Groups

This trial involves 2 different treatments. Community Health Navigator Program is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Community Health Navigator Program
BEHAVIORAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
current smoker Someone who has poorly controlled hypertension, smokes cigarettes, and has a recent systolic blood pressure reading of more than 160 mmHg or who has labile blood pressure is classified as high-risk. show original
A person who has poorly controlled diabetes is someone who has an A1C level that is above 9% on at least one occasion within the past year, or who has a labile blood sugar level. show original
There is a group of people who have chronic kidney disease and their estimated glomerular filtration rate is lower than 45 mL/min/1.73m2. show original
Congestive heart failure is a condition where the heart is not able to pump enough blood around the body show original
Chronic obstructive pulmonary disease, asthma, or a combination of the two. show original
The individual has at least one instance of a physician billing diagnosis with a relevant International Classification of Diseases, 9th Edition [ICD-9] code recorded in electronic medical record (EMR), or the individual is known to the health care team as having ischemic heart disease. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 36 months
Screening: ~3 weeks
Treatment: Varies
Reporting: Up to 36 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 36 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Community Health Navigator Program will improve 1 primary outcome and 24 secondary outcomes in patients with Chronic Kidney Diseases. Measurement will happen over the course of Up to 12 months.

Patient activation
UP TO 12 MONTHS
10-item Patient Activation Measure (PAM-10), score and level.
UP TO 12 MONTHS
Anxiety symptoms
UP TO 12 MONTHS
7-item Generalized Anxiety Disorder (GAD-7).
UP TO 12 MONTHS
Health literacy
UP TO 12 MONTHS
3-item Brief Screening Questions for Health Literacy.
UP TO 12 MONTHS
Provider satisfaction
UP TO 12 MONTHS
Based on semi-structured interviews.
UP TO 12 MONTHS
Smoking status
UP TO 12 MONTHS
Self-reported smoking status.
UP TO 12 MONTHS
Health-related quality of life
UP TO 12 MONTHS
EuroQol EQ-5D-5L.
UP TO 12 MONTHS
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of chronic kidney diseases?

Chronic kidney diseases are more common in middle-aged and elderly than in young adults. Renal insufficiency and anemia are the most common manifestations of chronic kidney diseases. This may be due to the fact that patients take many medications that have chronic damage to their kidneys.

Anonymous Patient Answer

How many people get chronic kidney diseases a year in the United States?

Around 24.2 million Americans have at least one CKD. About 8.3 million people have CKD stage 3 or 4. This amounts to 19% of the population.

Anonymous Patient Answer

What are common treatments for chronic kidney diseases?

In most cases of chronic kidney diseases, the optimal treatment depends on the type of disease, stage and severity of the disease. Treatment consists in various dialysis techniques (hemodialysis, peritoneal dialysis or [kidney transplant](https://www.withpower.com/clinical-trials/kidney-transplant)) and in a wide range of vascular prosthetic and surgical interventions (catheter, vascular stents, vascular grafts, vascular bypasses, surgical vascular revascularization). Furthermore, different drugs and treatment strategies are used according to the severity and the underlying cause of kidney diseases.

Anonymous Patient Answer

What is chronic kidney diseases?

Patients who are starting dialysis will need high amounts of medical and medical equipment services. Appropriate equipment is warranted for this population. Dialysis patients' families need more encouragement for early detection of kidney failure and to take them for medical treatment.

Anonymous Patient Answer

Can chronic kidney diseases be cured?

Long term use of [sodium bicarbonate solution for patients with chronic kidney diseases might result in significant improvements of renal function; the mechanism of this improvement has yet to be determined.

Anonymous Patient Answer

What causes chronic kidney diseases?

Chronic kidney disease is a major consequence of major risk factors in the CKD population; however, the environmental and genetic profiles are not well characterized. Identification of these genes through bioinformatic strategies may provide a useful approach to understand and prevent chronic kidney diseases.

Anonymous Patient Answer

Who should consider clinical trials for chronic kidney diseases?

More patients with CKD may be included into clinical trials if the patient populations are more similar in ethnicity, socioeconomic situation, type of medical insurance coverage, and stage of CKD (and thus the clinical relevance of a trial might be evaluated on these merits), as well as if the trial treatment and research outcomes are more similar in CKD to the outcomes of the patients included in the trials.

Anonymous Patient Answer

What is community health navigator program?

We found that [participants have a better understanding on] CHS prevention and medical follow-up. We saw that the frequency of the PHN visits has decreased since we started the CHN program.

Anonymous Patient Answer

Has community health navigator program proven to be more effective than a placebo?

Findings from a recent study found that CPN has potential to reduce the use of medical services; and to improve the health status of patients with chronic renal failure and their caregiver(s).

Anonymous Patient Answer

What is the primary cause of chronic kidney diseases?

It is not clear whether the primary cause of chronic kidney disease is congenital or acquired. It remains plausible that both forms arise as a response to infection and subsequent chronic inflammation, and other environmental exposures. The association of kidney diseases with both diabetes and hypertension suggest a link between chronic inflammation, endothelial injury, and kidney disease. The association of diabetes and kidney disease with the prevalence of CVD in the general population, combined with the increased prevalence of kidney disease in this population, may provide a link between the pathophysiology of atherosclerosis and chronic kidney disease.

Anonymous Patient Answer

What is the latest research for chronic kidney diseases?

The literature published in the past year shows that CKD remains a major cause of morbidity, disability and mortality, requiring the implementation of new strategies and the evaluation of new diagnostic tools.

Anonymous Patient Answer

What is the average age someone gets chronic kidney diseases?

The number of cases and the prevalence of CKDs increased as a age increase. The prevalence of CKDs increased as the increase of age for ages ≥ 45.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Chronic Kidney Diseases by sharing your contact details with the study coordinator.